ACT Genomics wins 2019 National Innovation Award


ACT Genomics’ ACTOnco®+ performs well and receives National Innovation Award, and is the only genomic profiling company receiving this honor in biopharma and precision medicine field. This technology analyzing more than 400 cancer genes for cancer precision medicine has received many international certifications, and is in application of US FDA IVD, which is highly competitive; ACT Genomics not only focuses on Taiwan Medical System, but actively expands its influence in Greater China, North East Asia and South East Asia, to get ahead in Asia Pacific market.

Image title